loading page

Efficacy and safety of phytoestrogens in the treatment of postmenopausal depressive disorders: a systematic review and meta-analysis
  • +5
  • Li Jieyun,
  • Huijuan LI,
  • Yan Peijing,
  • Liping Guo,
  • Jingwen Li,
  • Jiani Han,
  • Jie Qiu,
  • Kehu Yang
Li Jieyun
Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, PR China
Author Profile
Huijuan LI
Taiyuan Central Hospital, Taiyuan, PR China
Author Profile
Yan Peijing
Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University
Author Profile
Liping Guo
Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province
Author Profile
Jingwen Li
Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province
Author Profile
Jiani Han
Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University
Author Profile
Jie Qiu
Gansu Provincial Maternity and Child Care Hospital
Author Profile
Kehu Yang
Evidence Based Medicine Center
Author Profile

Abstract

Background:Depression is one of the most common and specific symptoms among postmenopausal women, leading to significant personal, family, and economic burdens. Some studies have shown that phytoestrogens can help relieve symptoms of depression. Objectives: This systematic review and meta-analysis aims to assess the efficacy and safety of phytoestrogens in treating depression among postmenopausal women. Methods: A comprehensive search for relevant studies published until November 25, 2020, was conducted in PubMed, the Cochrane Library, Chinese Biomedical Literature Database, Web of Science, and EMBASE. Statistical analyses were performed with Stata12.0, Comprehensive Meta-Analysis 3.0, and Review Manager 5.4. Results: 2,183 studies were identified and 10 studies were included, involving 1,248 participants. The quality of the four studies was assessed as high risk, six studies were assessed as unclear. The analyses conducted according random effects model indicated a positive effect on depressive symptoms for postmenopausal women compared to the placebo (SMD=-0.45; 95% [CI]= -0.60 to -0.29; Q=40.42, df=18, P=0.002; I2=55.5%). The high dose phytoestrogens (dose>100mg/day) have better effectiveness (SMD =-0.48; 95%[CI]= -0.76 to -0.20; I2=52.8%, P<0.05) than low dose (25mg/day≤dose≤100mg/day) (SMD=-0.45; 95%[CI]=-0.68 to-0.23; I2=66.7%; P>0.05) and ultralow dose (00.05). Isoflavones had better effectiveness (SMD=-0.52; 95% [CI]= -0.75 to 0.30; I2=65.8%, P<0.05) than lignans of phytoestrogens (SMD= -0.23; 95% [CI]= -0.05 to 0.01; I2=0%, P>0.05). The effectiveness varies in regions. The adverse reactions frequently reported were gastrointestinal symptoms and cold or upper respiratory tract infection. Conclusions: Phytoestrogen can relieve depression symptoms among postmenopausal women. High-dose isoflavones is the most effective. Although mild adverse reactions have been reported, phytoestrogen could be considered as a complementary treatment for postmenopausal depression.

Peer review status:ACCEPTED

21 Dec 2020Submitted to International Journal of Clinical Practice
21 Dec 2020Submission Checks Completed
21 Dec 2020Assigned to Editor
21 Dec 2020Reviewer(s) Assigned
27 Feb 2021Review(s) Completed, Editorial Evaluation Pending
21 Mar 20211st Revision Received
22 Mar 2021Submission Checks Completed
22 Mar 2021Assigned to Editor
23 Mar 2021Reviewer(s) Assigned
05 May 2021Review(s) Completed, Editorial Evaluation Pending
09 May 2021Editorial Decision: Accept